TGA strengthens denosumab safety information

Regulator updates warnings for fracture risk after discontinuation of Prolia and biosimilars  Safety information for denosumab (Prolia and equivalent biosimilar) products used to treat osteoporosis is being updated to strengthen existing warnings for spinal fractures after stopping or delaying treatment.   The Therapeutic Goods Administration (TGA) noted that “new spinal fractures have occurred as early